Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

• US 8,129,330 B2
• Filed: 09/25/2003
• Issued: 03/06/2012
• Est. Priority Date: 09/30/2002
• Status: Active Grant

• Current Assignee: Mountain View Pharmaceuticals, Inc.
• Original Assignee: Mountain View Pharmaceuticals, Inc.
• Inventors: Saifer, Mark G. P., Williams, L. David, Martinez, Alexa L, Sherman, Merry R
• Primary Examiner(s): Gupta, Anish
• Application Number:
  US10/669,597
• Publication Number:
  US 20040062746A1
• Time in Patent Office: 3,085 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/646 the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: C08G 65/3322 : acyclic
• CPC Class Codes: C08G 65/3332 : containing carboxamide group
• CPC Class Codes: C08G 65/3356 : having nitrogen in addition to phosphorus
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Y 107/03003 : Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Abstract

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Claims

1. A composition comprising a conjugate 95% or more pure, said conjugate comprising a peptide, protein or glycoprotein covalently attached to at least one linear or branched polyalkylene glycol(s),

wherein said linear or branched polyalkylene glycol(s) is or are attached to said peptide, protein or glycoprotein at a single site on said linear or branched polyalkylene glycol(s),

wherein a hydroxyl group is present on all of the distal polyalkylene glycol termini in said pure conjugate, and

wherein said pure conjugate exhibits reduced antigenicity compared to a second conjugate comprising the same peptide, protein or glycoprotein linked at the same site or sites on the peptide, protein or glycoprotein to the same number of polyalkylene glycol(s) of the same size and the same linear or branched structure, wherein an alkoxyl or an aryloxyl group is present on the distal polyalkylene glycol termini in said second conjugate.

2. The composition of claim 1, wherein each of said linear or branched polyalkylene glycol(s) is selected from the group consisting of a poly(ethylene glycol) and a copolymer of ethylene oxide and propylene oxide.

3. The composition of claim 2, wherein each of said linear or branched polyalkylene glycol(s) is a poly(ethylene glycol) (“

PEG”

).

4. The composition of claim 3, wherein the attachment of said PEG to said peptide, protein or glycoprotein is carried out using a monofunctionally activated derivative of at least one PEG selected from the group consisting of a linear dihydroxyPEG, a hydroxyPEG-monoacetal and a hydroxyPEG-monoacid.

5. The composition of claim 3, wherein the attachment of said PEG to said peptide, protein or glycoprotein is carried out using a monofunctionally activated derivative of hydroxyPEG selected from the group consisting of a monoaldehyde, a monoester of a monoacid, a monoamine, a monothiol, a monodisulfide, a monobromophenyl carbonate, a monochlorophenyl carbonate, a monofluorophenyl carbonate, a mononitrophenyl carbonate, a monocarbonylimidazole, a monohydrazide, a monocarbazate, a monoiodoacetamide, a monomaleimide, a monoorthopyridyl disulfide, a monooxime, a monophenyl glyoxal, a monothiazolidine-2-thione, a monothioester, a monotriazine and a monovinylsulfone.

6. The composition of claim 1, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 1,000 Daltons (1 kDa) to about 100,000 Daltons (100 kDa).

7. The composition of claim 6, wherein each of said linear or branched polyalkylene glycol(s) has two branches, each with a molecular weight of from about 2 kDa to about 30 kDa.

8. The composition of claim 7, wherein each of said linear or branched polyalkylene glycol(s) has two branches, each with a molecular weight of from about 5 kDa to about 20 kDa.

9. The composition of claim 6, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 10 kDa to about 20 kDa.

10. The composition of claim 9, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of about 12 kDa.

11. The composition of claim 6, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 18 kDa to about 60 kDa.

12. The composition of claim 11, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 18 kDa to about 22 kDa.

13. The composition of claim 12 wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of about 20 kDa.

14. The composition of claim 11, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of about 27 kDa to about 33 kDa.

15. The composition of claim 1, wherein said peptide, protein or glycoprotein is attached to from one to about 100 molecules of said linear or branched polyalkylene glycol(s).

16. The composition of claim 15, wherein said peptide, protein or glycoprotein is attached to from one to about five molecules of said linear or branched polyalkylene glycol(s).

17. The composition of claim 16, wherein said peptide, protein or glycoprotein is attached to one or two molecules of said linear or branched polyalkylene glycol(s).

18. The conjugate of claim 15, wherein said peptide, protein or glycoprotein is attached to about five to about 100 molecules of said linear or branched polyalkylene glycol(s).

19. The composition of claim 1, wherein each of said linear or branched polyalkylene glycol(s) is selected from the group consisting of a monohydroxyPEG-acid and a di(hydroxyPEG)-acid.

20. The composition of claim 4, wherein the attachment of said PEG to said peptide, protein or glycoprotein is carried out using said monofunctionally activated derivative of said linear dihydroxyPEG.

21. The composition of claim 4, wherein the attachment of said PEG to said peptide, protein or glycoprotein is carried out using said monofunctionally activated derivative of said hydroxyPEG-monoacid.

22. The composition of claim 1, wherein said peptide, protein or glycoprotein is an allergen.

23. The composition of claim 1, wherein said composition is a pharmacuatical composition comprising a pharmaceutically acceptable excipient or carrier.

24. The composition of claim 1, wherein said peptide, protein or glycoprotein is covalently attached to at least one linear or branched polyalkylene glycol that had been converted to a monofunctionally activated polyalkylene glycol by a method comprising:

(a) obtaining a polyalkylene glycol that has a hydroxyl group at every terminus;

(b) prior to the conversion of the polyalkylene glycol of (a) to a monofunctionally activated polyalkylene glycol, protecting all except one of the hydroxyl groups in said polyalkylene glycol by the addition of one or more removable blocking groups to obtain a protected monohydroxy polyalkylene glycol;

(c) producing a monofunctionally activated derivative of said protected polyalkylene glycol of (b) by reacting said protected polyalkylene glycol of (b) with a derivatizing compound or compounds under conditions such that said protected polyalkylene glycol of (b) is derivatized with a single derivatizing group at a hydroxyl group that does not contain said removable blocking group or groups of (b);

(d) purifying said monofunctionally activated derivative of (c);

(e) removing said blocking group or groups of (b) from said monofunctionally activated derivative of (d) without removing the derivatizing group attached in (c), to produce a monofunctionally activated polyalkylene glycol wherein the distal terminus or distal termini are hydroxyl group(s); and

(f) contacting said monofunctionally activated polyalkylene glycol of (e) with said peptide, protein or glycoprotein under conditions that favor the covalent attachment of said monofunctionally activated polyalkylene glycol to said peptide, protein or glycoprotein.

25. The composition of claim 24, wherein each of said linear or branched polyalkylene glycol(s) is selected from the group consisting of a poly(ethylene glycol) and a copolymer of ethylene oxide and propylene oxide.

26. The composition of claim 24, wherein each of said linear or branched polyalkylene glycol(s) is selected from the group consisting of a linear poly(ethylene glycol) and a branched poly(ethylene glycol).

27. The composition of claim 24, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 1 kDa to about 100 kDa.

28. The composition of claim 27, wherein each of said linear or branched polyalkylene glycol(s) has two branches, each with a molecular weight of from about 2 kDa to about 30 kDa.

29. The composition of claim 27, wherein each of said linear or branched polyalkylene glycol(s) has a molecular weight of from about 10 kDa to about 20 kDa.

30. The composition of claim 24, wherein said peptide, protein or glycoprotein is attached to from one to about 100 molecules of said linear or branched polyalkylene glycol(s).

31. The composition of claim 30, wherein said peptide, protein or glycoprotein is attached to from one to about five molecules of said linear or branched polyalkylene glycol(s).

32. The composition of claim 31, wherein said peptide, protein or glycoprotein is attached to one or two molecules of said linear or branched polyalkylene glycol(s).

33. The composition of claim 30, wherein said peptide, protein or glycoprotein is attached to about five to about 100 moleculed of said linear or branched polyalkylene glycol(s).

34. The conjugate of claim 24, wherein said monofunctionally activated polyalkylene glycol of (e) is selected from the group consisting of a hydroxyPEG-monoaldehyde and a reactive ester of a hydroxyPEG-monoacid.

35. The composition of claim 24, wherein said monofunctionally activated polyalkylene glycol is derived from a linear dihydroxyPEG.

36. The composition of claim 24, wherein said peptide, protein or glycoprotein is an allergen.

37. A kit comprising more than one container, at least one of said containers comprising the composition of claim 1.

38. The composition of claim 19, wherein each of said linear or branched polyalkylene glycol(s) is di(hydroxyPEG)-lysine.

39. The composition of claim 1, wherein said peptide or protein or glycoprotein is selected from the group consisting of an enzyme, a serum protein, a serum glycoprotein, a blood cell protein, a pigmentary protein, hemoglobin, a viral protein, a peptide hormone, a protein hormone, a glycoprotein hormone, a hypothalamic releasing factor, a cytokine and a growth factor.

40. The composition of claim 39, wherein said peptide, protein or glycoprotein is a serum protein and is selected from the group consisting of an albumin, an immunoglobulin and a blood clotting factor.

41. The composition of claim 39, wherein said peptide, protein or glycoprotein is a peptide hormone or protein hormone or glycoprotein hormone and is selected from the group consisting of an antidiuretic hormone, chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, insulin, prolactin, a somatomedin, growth hormone, thyroid-stimulating hormone and a placental lactogen.

42. The composition of claim 39, wherein said peptide, protein or glycoprotein is a growth growth factor and is selected from the group consisting of a colony-stimulating factor, an epidermal growth factor, an erythropoietin, a fibroblast growth factor, an insulin-like growth factor, a transforming growth factor, a platelet-derived growth factor, a nerve growth factor, a hepatocyte growth factor, a neurotrophic factor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, a glial-derived neurotrophic factor and a bone morphogenic peptide.

43. The composition of claim 39, wherein said peptide, protein or glycoprotein is a cytokine and is selected from the group consisting of a lymphokine, an interleukin, an interferon, a tumor necrosis factor, a leukemia inhibitory factor and thrombopoietin.

44. The composition of claim 39, wherein said peptide, protein or glycoprotein is an enzyme and is selected from the group consisting of a carbohydrate-specific enzyme, a proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase and a ligase.

45. The composition of claim 44, wherein said enzyme is a uricase.

46. The composition of claim 44, wherein said enzyme is a plasminogen activator.

47. The composition of claim 24, wherein said peptide, protein or glycoprotein is selected from the group consisting of an enzyme, a serum protein, a serum glycoprotein, a blood cell protein, a pigmentary protein, hemoglobin, a viral protein, a peptide hormone, a protein hormone, a glycoprotein hormone, a hypothalamic releasing factor, a cytokine and a growth factor.

48. The composition of claim 47, wherein said peptide, protein or glycoprotein is a serum protein and is selected from the group consisting of an albumin, an immunoglobulin and a blood-clotting factor.

49. The composition of claim 47, wherein said peptide, protein or glycoprotein is a peptide hormone or protein hormone or glycoprotein hormone and is selected from the group consisting of an antidiuretic hormone, chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, insulin, prolactin, a somatomedin, growth hormone, thyroid-stimulating hormone and a placental lactogen.

50. The composition of claim 47, wherein said peptide, protein or glycoprotein is a growth factor and is selected from the group consisting of a colony-stimulating factor, an epidermal growth factor, an erythropoietin, a fibroblast growth factor, an insulin-like growth factor, a transforming growth factor, a platelet-derived growth factor, a nerve growth factor, a hepatocyte growth factor, a neurotrophic factor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, a glial-derived neurotrophic factor and a bone morphogenic peptide.

51. The composition of claim 47, wherein said peptide, protein or glycoprotein is a cytokine and is selected from the group consisting of a lymphokine, an interleukin, an interferon, a tumor necrosis factor, a leukemia inhibitory factor and thrombopoietin.

52. The composition of claim 47, wherein said peptide, protein or glycoprotein is an enzyme and is selected from the group consisting of a carbohydrate-specific enzyme, a proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase and a ligase.

53. The composition of claim 52, wherein said enzyme is a uricase.

54. The composition of claim 52, wherein said enzyme is a plasminogen activator.

55. The composition of claim 39, wherein said peptide, protein or glycoprotein is a colony-stimulating factor.

56. The composition of claim 55, wherein said colony-stimulating factor is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

57. The composition of claim 56, wherein said GM-CSF is covalently attached to one linear or branched polyalkylene glycol molecule.

58. The composition of claim 56, wherein said GM-CSF is covalently attached to two linear or branched polyalkylene glycol molecules.

59. The composition of claim 47, wherein said peptide, protein or glycoprotein is a colony-stimulating factor.

60. The composition of claim 59, wherein said colony-stimulating factor is a GM-CSF.

61. The composition of claim 42, wherein said peptide, protein or glycoprotein is an erythropoietin.

62. The composition of claim 50, wherein said peptide, protein or glycoprotein is an erythropoietin.

63. The composition of claim 16, wherein said peptide, protein or glycoprotein is attached to from one to three molecules of said linear or branched polyalkylene glycol(s).

64. The composition of claim 24, wherein said peptide, protein or glycoprotein is attached to from one to three molecules of said linear or branched polyalkylene glycol(s).

65. The composition of claim 1, wherein said pure conjugate is 98% or more pure.

66. The composition of claim 1, wherein said pure conjugate is 99% or more pure.

67. The composition of claim 24, wherein said one or more removable blocking groups is or are selected from the group consisting of t-butoxyl groups, aryloxyl groups, and triphenylmethyl groups.

68. The composition of claim 24, wherein said contacting (f) is performed prior to said removing (e).

69. The composition of claim 1, wherein said peptide, protein or glycoprotein is covalently attached to at least one linear or branched polyalkylene glycol that had been activated at only one terminus produced by a method comprising:

obtaining a polyalkylene glycol that has a hydroxyl group at every terminus;

producing a monofunctionally activated derivative of said polyalkylene glycol of (a) by reacting said polyalkylene glycol of (a) with a derivatizing compound or compounds under conditions such that a monofunctionally activated derivative of said polyalkylene glycol of (a) is formed;

(c) purifying said monofunctionally activated derivative of (b); and

(d) contacting said purified monofunctionally activated derivative of (c) with said peptide, protein or glycoprotein under conditions that favor the covalent attachment of said purified monofunctionally activated derivative of (c) to said peptide, protein or glycoprotein.

70. The composition of claim 69, wherein said polyalkylene glycol of (a) is selected from the group consisting of a poly(ethylene glycol) and a copolymer of ethylene oxide and propylene oxide.

71. The composition of claim 69, wherein said polyalkylene glycol of (a) is selected from the group consisting of a linear poly(ethylene glycol) and a branched poly(ethylene glycol).

72. The composition of claim 69, wherein each said polyalkylene glycol of (a) has a molecular weight of from about 1 kDa to about 100 kDa.

73. The composition of claim 72, wherein said polyalkylene glycol of (a) has two branches, each with a molecular weight of from about 2 kDa to about 30 kDa.

74. The composition of claim 72, wherein said polyalkylene glycol of (a) has a molecular weight of from about 10 kDa to about 20 kDa.

75. The composition of claim 69, wherein said peptide, protein or glycoprotein is attached to from one to about 100 molecules of said linear or branched polyalkylene glycol(s).

76. The composition of claim 75, wherein said peptide, protein or glycoprotein is attached to from one to about five molecules of said linear or branched polyalkylene glycol(s).

77. The composition of claim 76, wherein said peptide, protein or glycoprotein is attached to one or two molecules of said linear or branched polyalkylene glycol(s).

78. The composition of claim 75, wherein said peptide, protein or glycoprotein is attached to about five to about 100 molecules of said linear or branched polyalkylene glycol(s).

79. The composition of claim 69, wherein said purified monofunctionally activated derivative of (c) is selected from the group consisting of a hydroxyPEG-monoaldehyde and a reactive ester of a hydroxyPEG-monoacid.

80. The composition of claim 69, wherein said polyalkylene glycol of (a) is a linear dihydroxyPEG.

81. The composition of claim 69, wherein said peptide, protein or glycoprotein is an allergen.

82. A pharmaceutical composition comprising the composition of claim 69 and a pharmaceutically acceptable excipient or carrier.

83. The pharmaceutical composition of claim 82, wherein said peptide, protein or glycoprotein is selected from the group consisting of an enzyme, a serum protein, a serum glycoprotein, a blood cell protein, a pigmentary protein, hemoglobin, a viral protein, a peptide hormone, a protein hormone, a glycoprotein hormone, a hypothalamic releasing factor, a cytokine and a growth factor.

84. The pharmaceutical composition of claim 83, wherein said peptide, protein or glycoprotein is a serum protein and is selected from the group consisting of an albumin, an immunoglobulin and a blood-clotting factor.

85. The pharmaceutical composition of claim 83, wherein said peptide hormone or protein hormone or glycoprotein hormone is selected from the group consisting of an antidiuretic hormone, chorionic gonadotropin, luteinizing hormone, follicle-stimulating hormone, insulin, prolactin, a somatomedin, growth hormone, thyroid-stimulating hormone and a placental lactogen.

86. The pharmaceutical composition of claim 83, wherein said peptide, protein or glycoprotein is a growth factor and is selected from the group consisting of a colony-stimulating factor, an epidermal growth factor, an erythropoietin, a fibroblast growth factor, an insulin-like growth factor, a transforming growth factor, a platelet-derived growth factor, a nerve growth factor, a hepatocyte growth factor, a neurotrophic factor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, a glial-derived neurotrophic factor and a bone morphogenic peptide.

87. The pharmaceutical composition of claim 83, wherein said peptide, protein or glycoprotein is a cytokine and is selected from the group consisting of a lymphokine, an interleukin, an interferon, a tumor necrosis factor, a leukemia inhibitory factor and thrombopoietin.

88. The pharmaceutical composition of claim 83, wherein said peptide, protein or glycoprotein is an enzyme and is selected from the group consisting of a carbohydrate-specific enzyme, a proteolytic enzyme, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase and a ligase.

89. The pharmaceutical composition of claim 88, wherein said enzyme is a uricase.

90. The pharmaceutical composition of claim 88, wherein said enzyme is a plasminogen activator.

91. The pharmaceutical composition of claim 83, wherein said peptide, protein or glycoprotein is a colony-stimulating factor.

92. The pharmaceutical composition of claim 91, wherein said colony-stimulating factor is a GM-CSF.

93. The pharmaceutical composition of claim 86, wherein said growth factor is an erythropoietin.

94. The composition of claim 76 , wherein said peptide, protein or glycoprotein is attached to from one to three molecules of said linear or branched polyalkylene glycol(s).